Literature DB >> 25966743

The Dynamic cerebral autoregulatory adaptive response to noradrenaline is attenuated during systemic inflammation in humans.

Ronan M G Berg1,2, Ronni R Plovsing3,4, Damian M Bailey5, Niels-Henrik Holstein-Rathlou6, Kirsten Møller2,7.   

Abstract

Vasopressor support is used widely for maintaining vital organ perfusion pressure in septic shock, with implications for dynamic cerebral autoregulation (dCA). This study investigated whether a noradrenaline-induced steady state increase in mean arterial blood pressure (MAP) would enhance dCA following lipopolysaccharide (LPS) infusion, a human-experimental model of the systemic inflammatory response during early sepsis. The dCA in eight healthy males was examined prior to and during an intended noradrenaline-induced MAP increase of approximately 30 mmHg. This was performed at baseline and repeated after a 4-h intravenous LPS infusion. The assessments of dCA were based on transfer function analysis of spontaneous oscillations between MAP and middle cerebral artery blood flow velocity measured by transcranial Doppler ultrasound in the low frequency range (0.07-0.20 Hz). Prior to LPS, noradrenaline administration was associated with a decrease in gain (1.18 (1.12-1.35) vs 0.93 (0.87-0.97) cm/mmHg per s; P < 0.05) with no effect on phase (0.71 (0.93-0.66) vs 0.94 (0.81-1.10) radians; P = 0.58). After LPS, noradrenaline administration changed neither gain (0.91 (0.85-1.01) vs 0.87 (0.81-0.97) cm/mmHg per s; P = 0.46) nor phase (1.10 (1.04-1.30) vs 1.37 (1.23-1.51) radians; P = 0.64). The improvement of dCA to a steady state increase in MAP is attenuated during an LPS-induced systemic inflammatory response. This may suggest that vasopressor treatment with noradrenaline offers no additional neuroprotective effect by enhancing dCA in patients with early sepsis.
© 2015 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  cerebral blood flow; endotoxin; lipopolysac-charide; sepsis; sepsis-associated encephalopathy; vasopressor

Mesh:

Substances:

Year:  2015        PMID: 25966743     DOI: 10.1111/1440-1681.12421

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  6 in total

1.  What is a Clinician to Do?

Authors:  Clifford S Deutschman
Journal:  Crit Care Med       Date:  2018-07       Impact factor: 7.598

2.  Diagnostic and prognostic performance of Mxa and transfer function analysis-based dynamic cerebral autoregulation metrics.

Authors:  Markus Harboe Olsen; Christian Riberholt; Ronni R Plovsing; Ronan Mg Berg; Kirsten Møller
Journal:  J Cereb Blood Flow Metab       Date:  2022-08-25       Impact factor: 6.960

3.  Ischemic lesions, blood pressure dysregulation, and poor outcomes in intracerebral hemorrhage.

Authors:  Chelsea S Kidwell; Jonathan Rosand; Gina Norato; Simone Dixon; Bradford B Worrall; Michael L James; Mitchell S V Elkind; Matthew L Flaherty; Jennifer Osborne; Anastasia Vashkevich; Carl D Langefeld; Charles J Moomaw; Daniel Woo
Journal:  Neurology       Date:  2017-01-25       Impact factor: 9.910

4.  Evaluation of Brain Nuclear Medicine Imaging Tracers in a Murine Model of Sepsis-Associated Encephalopathy.

Authors:  Dávid Szöllősi; Nikolett Hegedűs; Dániel S Veres; Ildikó Futó; Ildikó Horváth; Noémi Kovács; Bernadett Martinecz; Ádám Dénes; Daniel Seifert; Ralf Bergmann; Ondřej Lebeda; Zoltán Varga; Zoltán Kaleta; Krisztián Szigeti; Domokos Máthé
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

Review 5.  Regulation of the cerebral circulation: bedside assessment and clinical implications.

Authors:  Joseph Donnelly; Karol P Budohoski; Peter Smielewski; Marek Czosnyka
Journal:  Crit Care       Date:  2016-05-05       Impact factor: 9.097

6.  The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature.

Authors:  Logan Froese; Joshua Dian; Alwyn Gomez; Bertram Unger; Frederick A Zeiler
Journal:  Pharmacol Res Perspect       Date:  2020-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.